On July 14, 2025, NKGen Biotech, Inc. entered a collaboration with HekaBio K.K. for developing and commercializing its SNK01 therapy in Japan, where HekaBio will handle commercialization and regulatory tasks. The profit-sharing arrangement provides HekaBio with 70% of product profits initially, decreasing to 45% after cost recovery, while the company keeps 55%.